Cue Biopharma
NASDAQ: CUEBoston, US · Founded 2014 · Delaware corporation · 1 known investors
Find your way into Cue Biopharma
792 people in our graph share verified history with the Cue Biopharma team — schools, employers, funds. One of them is your warm intro.
Ken Chenaultunlockedknows Sumita Ray · together at Chief (overlapped)
×4knows the team · via Chief
knows the team · via Women In Bio - Engage. Educate. Empower.
×3knows the team · via Université Paris Cité
knows the team · via Amgen
×2knows the team · via AstraZeneca Pharmaceuticals LP
Cue Biopharma is a precision immunotherapy company developing engineered therapies targeting allergic and autoimmune diseases. The company's pipeline includes CUE-221 for IgE-mediated allergic disease and CUE-401 advancing from its proprietary Immuno-STAT platform for autoimmune conditions.
Founders & leadership
DB
Daniel BakerExecutive
CS
Colin SandercockExecutive
DB
Dominic BorieinChief Medical Officer and Head of R&DDominic Borie is a physician-scientist and immunologist with over 20 years of pharmaceutical industry experience in drug development, clinical trial design, and medical affairs. He previously founded and served as CEO of a biotech company developing treatments for autoimmune diseases before joining Cue Biopharma as Chief Medical Officer and Head of Research and Development.
SR
Sumita RayinChief Legal & Compliance Officer and Corporate SecretarySumita Ray is an executive officer at Cue Biopharma with over 25 years of experience in pharmaceutical and biotechnology law, regulatory affairs, and compliance. She has held in-house legal and general & administrative leadership roles across regulatory, commercial, and compliance functions.
MM
Michael MeluzioinVP of Finance
RC
Rodolfo ChaparroVice President, Head of Immunology
RS
Ronald Seidel IIIExecutive Vice President, Head of Research and Development
GS
Gary SchumanChief Financial Officer
CG
Cameron GrayChief Executive Officer and President
JM
James M. AhlersCFO
AD
Anthony DiGiandomenicoNamed on SEC filing
Board
PV
Patrick VerheyenBoard director
Investors · 1
Funding
SEC filings, press & company announcements$186.4M disclosed across 6 of 7 rounds · 2015–2026
- $50MraisedJul 2026Source ↗
▶$50MraisedJul 2026 · 4 investors · BiotechnologyRule 506(b)
▶$50MraisedJul 2026 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Shao-Lee LinExecutive Officer, Director
- Dominic BorieExecutive Officer
- Sumita RayExecutive Officer
- Daniel CamardoDirector
- Pamela GarzoneDirector
- Viola MeehanDirector
- Pasha SarrafDirector
- Michael MeluzioExecutive Officer
- Offering amount
- $50M
- Amount sold
- $50M
- First sale
- Jul 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$30MraisedMay 2026 · 118 investors · BiotechnologyRule 506(b)
▶$30MraisedMay 2026 · 118 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Patrick VerheyenDirector
- Daniel BakerExecutive Officer
- Peter KienerDirector
- Frank MorichDirector
- Pamela D. GarzoneDirector
- Colin SandercockExecutive Officer
- Jill M. BroadfootDirector
- Shao-Lee LinExecutive Officer, Director
- Pasha SarrafDirector
- Offering amount
- $30M
- Amount sold
- $30M
- Sales commissions
- $1.8M
- Placement agents
- Newbridge Securities Corporation
- First sale
- May 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$30MraisedNov 2022 · 64 investors · BiotechnologyRule 506(b)
▶$30MraisedNov 2022 · 64 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Tamar HowsonDirector
- Daniel R. PasseriExecutive Officer, Director
- Aaron FletcherDirector
- Peter A. KienerDirector
- Kerri-Ann MillarExecutive Officer
- Anish SuriExecutive Officer
- Frank MorichDirector
- Frederick DriscollDirector
- Patricia NasshornExecutive Officer
- Colin G. SandercockExecutive Officer
- Ken PientaExecutive Officer
- Offering amount
- $30M
- Amount sold
- $30M
- Sales commissions
- $1.8M
- Placement agents
- Public Ventures, LLC, Piper Sandler & Co.
- First sale
- Nov 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$16.4MraisedDec 2016 · 133 investors · BiotechnologyRule 506(b)
▶$16.4MraisedDec 2016 · 133 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- RONALD SEIDEL IIIExecutive Officer
- ANTHONY DIGIANDOMENICODirector
- CAMERON GRAYDirector
- GARY SCHUMANExecutive Officer
- STEVEN MCKNIGHTDirector
- AMY WANGDirector
- RODOLFO CHAPARROExecutive Officer
- DANIEL PASSERIExecutive Officer, Director
- CHRISTOPHER MARLETTDirector
- PETER KIENERDirector
- BARRY SIMONDirector
- Offering amount
- $16.4M
- Amount sold
- $16.4M
- Sales commissions
- $1.3M
- Placement agents
- MDB Capital Group, LLC
- First sale
- Dec 2016
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$10MraisedJun 2015 · 121 investors · BiotechnologyRule 506(b)
▶$10MraisedJun 2015 · 121 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Gary SchumanExecutive Officer, Director
- Christopher MarlettDirector
- Steven AlmoExecutive Officer
- Ronald Seidel IIIExecutive Officer
- Anthony DiGiandomenicoDirector
- Cameron GrayExecutive Officer, Director
- Amy WangExecutive Officer, Director
- Rodolfo ChaparroExecutive Officer
- Offering amount
- $10M
- Amount sold
- $10M
- Sales commissions
- $1M
- Placement agents
- MDB Capital Group, LLC
- First sale
- Jun 2015
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
▶$1MofferedJun 2015 · 1 investors · BiotechnologyRule 506(b)
▶$1MofferedJun 2015 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Rodolfo ChaparroExecutive Officer
- Ronald Seidel IIIExecutive Officer
- Christopher MarlettDirector
- Gary SchumanExecutive Officer, Director
- Cameron GrayExecutive Officer, Director
- Anthony DiGiandomenicoDirector
- Amy WangExecutive Officer, Director
- Steven AlmoExecutive Officer
- Offering amount
- $1M
- First sale
- Jun 2015
- Incorporated
- Corporation, Delaware, 2014
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$154.8Mvaluation at IPODec 2017 · $7.50/share · 424B1
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Competitors · 4
by search overlapKite Pharma20 shared keywordsKite develops CAR T-cell therapies that engineer a patient's own immune cells to target and destroy cancer cells. The company focuses on cell therapy treatments for cancers such as diffuse large B-cell lymphoma.
Seeking Alpha16 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
IQVIA15 shared keywordsIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.
Robinhood15 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Companies competing with Cue Biopharma for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights | The Manila Timesmanilatimes.net · Aug 2026
Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission - BioSpacebiospace.com · Aug 2026
Cue Biopharma Appoints Veteran James Ahlers as CFO - TipRanks.comtipranks.com · Aug 2026Frequently asked questions
- What does Cue Biopharma do?
- Cue Biopharma is a precision immunotherapy company developing engineered therapies targeting allergic and autoimmune diseases. The company's pipeline includes CUE-221 for IgE-mediated allergic disease and CUE-401 advancing from its proprietary Immuno-STAT platform for autoimmune conditions.
- Who are Cue Biopharma's investors?
- Cue Biopharma's investors include Bios Partners.
- How much funding has Cue Biopharma raised?
- Cue Biopharma has disclosed $186.4M raised across 6 of its 7 known rounds.
- Where is Cue Biopharma headquartered?
- Cue Biopharma is headquartered in Boston, US.